Shares of USANA Health Sciences, Inc. (NYSE:USNA - Get Free Report) reached a new 52-week low on Tuesday . The stock traded as low as $27.58 and last traded at $28.03, with a volume of 59771 shares traded. The stock had previously closed at $27.98.
Analysts Set New Price Targets
A number of equities research analysts have weighed in on the company. DA Davidson reduced their price objective on USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating for the company in a research note on Thursday, February 27th. Sidoti cut USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, February 18th. Finally, StockNews.com cut USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research note on Friday, February 14th.
Get Our Latest Stock Report on USNA
USANA Health Sciences Stock Down 0.2 %
The firm has a market cap of $515.44 million, a price-to-earnings ratio of 9.63, a price-to-earnings-growth ratio of 0.93 and a beta of 0.98. The stock has a fifty day moving average price of $31.81 and a 200-day moving average price of $35.47.
USANA Health Sciences (NYSE:USNA - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.49 by $0.15. The business had revenue of $213.61 million for the quarter, compared to analyst estimates of $208.82 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. As a group, research analysts expect that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current year.
Insider Buying and Selling
In other USANA Health Sciences news, CEO Jim Brown sold 5,000 shares of the company's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $29.47, for a total value of $147,350.00. Following the sale, the chief executive officer now owns 15,716 shares of the company's stock, valued at approximately $463,150.52. This represents a 24.14 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Joshua Foukas sold 5,732 shares of the company's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $32.54, for a total value of $186,519.28. The disclosure for this sale can be found here. Insiders have sold 15,920 shares of company stock valued at $500,285 over the last quarter. Company insiders own 0.33% of the company's stock.
Institutional Trading of USANA Health Sciences
Several large investors have recently bought and sold shares of USNA. Pacer Advisors Inc. grew its holdings in USANA Health Sciences by 16.5% in the third quarter. Pacer Advisors Inc. now owns 544,256 shares of the company's stock valued at $20,638,000 after purchasing an additional 76,904 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of USANA Health Sciences by 7.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 773,228 shares of the company's stock valued at $27,751,000 after acquiring an additional 55,059 shares in the last quarter. Pzena Investment Management LLC lifted its position in USANA Health Sciences by 3.6% during the fourth quarter. Pzena Investment Management LLC now owns 1,087,076 shares of the company's stock worth $39,015,000 after buying an additional 37,466 shares during the period. Jane Street Group LLC lifted its position in USANA Health Sciences by 330.0% during the fourth quarter. Jane Street Group LLC now owns 39,979 shares of the company's stock worth $1,435,000 after buying an additional 30,681 shares during the period. Finally, Norges Bank purchased a new position in USANA Health Sciences during the fourth quarter worth about $953,000. Institutional investors and hedge funds own 54.25% of the company's stock.
About USANA Health Sciences
(
Get Free Report)
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
Further Reading
Before you consider USANA Health Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and USANA Health Sciences wasn't on the list.
While USANA Health Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
